Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia
- 1 July 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 50 (1), 137-142
- https://doi.org/10.1161/hypertensionaha.107.087700
Abstract
Concentrations of soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) increase in maternal blood with the approach of clinical preeclampsia. Although alterations in these circulating antiangiogenic factors herald the signs and symptoms of preeclampsia, in vitro studies suggest they may also play a role in regulating early placental cytotrophoblast functions. Early pregnancy changes in sFlt1 and sEng may thus identify women destined to develop preeclampsia. We performed a nested case-control study of 39 women who developed preeclampsia and 147 contemporaneous normotensive controls each with serum collected in the first (11 to 13 weeks of gestation) and second (17 to 20 weeks) trimesters. Whereas levels of sFlt1 and sEng at 11 to 13 weeks were similar between cases and controls (sFlt1: 3.5±0.3 ng/mL versus 3.0±0.1, P=0.14; sEng 6.9±0.3 ng/mL versus 6.6±0.2, P=0.37, respectively), at 17 to 20 weeks both were elevated in the women destined to develop preeclampsia (sFlt1: 4.1±0.5 ng/mL versus 3.1±0.1, PPdelta{d}] between second and first trimester levels: dsFlt1, 0.63±0.91 ng/mL in preterm PE versus 0.05±0.15 in controls; dsEng, 0.73±0.77 ng/mL versus −1.32±0.18, P<0.01. Similar findings were noted in a cross-sectional analysis of specimens collected from the Calcium for Preeclampsia Prevention Study. In conclusion, sequential changes in antiangiogenic factors during early pregnancy may be useful for predicting preterm preeclampsia.This publication has 18 references indexed in Scilit:
- Soluble Endoglin and Other Circulating Antiangiogenic Factors in PreeclampsiaThe New England Journal of Medicine, 2006
- Soluble endoglin contributes to the pathogenesis of preeclampsiaNature Medicine, 2006
- Latest Advances in Understanding PreeclampsiaScience, 2005
- Pre-eclampsiaThe Lancet, 2005
- World Health Organization Systematic Review of Screening Tests for PreeclampsiaObstetrics & Gynecology, 2004
- Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insightsSeminars in Nephrology, 2004
- Maternal Serum sFlt1 Concentration Is an Early and Reliable Predictive Marker of PreeclampsiaClinical Chemistry, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaThe New England Journal of Medicine, 2004
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJCI Insight, 2003
- Practice bulletin #33: diagnosis and management of preeclampsia and eclampsiaObstetrics & Gynecology, 2002